Perspective: Defects in cell cycle control and cancer

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 95-99

  Bartek, Jiri ^a   Lukas, Jiri ^a   Bartkova, Jirina ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

CDK inhibitor; Cell cycle; Checkpoint; Cyclin; Cyclin dependent kinase; Oncogene; RB pathway; Tumour suppressor

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE;

CANCER; CARCINOGENESIS; CELL CYCLE; CHROMOSOME ABERRATION; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0032960739     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9896(199901)187:1<95::aid-path249>3.0.co;2-%23     Document Type: Review

References (23)

1. Hall M. Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human canter. Adv Cancer Res 1996; 68: 67-108.
2. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
3. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nature Med 1995; 1: 1245-1246.
4. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237: 1-6.
5. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274: 1664-1671.
6. Hartwell LH, Kastan MB. Cell cycle and cancer. Science 1994; 266: 1821-1828.
7. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997; 72: 1-25.
8. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126.
9. Hunter T. Oncoprotein networks. Cell 1997; 88: 333-346.
10. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Scienee 1997; 278: 1043-1050.
11. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors on the cyclin D/CDK-pRB-controlled G1 checkpoint. Mol Cell Biol 1996; 16: 6917-6925.
12. Peeper DS, Upton TM, Ladha MH, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 1997; 386: 177-181.
13. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8: 805-814.
14. Weinert T. A DNA damage checkpoint meets the cell cycle engine. Science 1997; 277: 1450-1451.
15. Rolfe M, Chiu MI, Pagano M. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med 1997; 75: 5-17.
16. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16. Cell 1997; 88: 593-602.
17. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med 1997; 3: 1034-1036.
18. Weinberg RA. E2F and cell proliferation: a world turned upside down. Cell 1996; 85: 457-459.
19. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Der 1997; 11: 847-862.
20. WAF1/Cip1 mutants deficient in inhibiting cyclin-dependent kinases can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells. Cancer Res. 1998; 58 (in press).
21. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D3: requirement for GI/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogcne 1998; 17: 1027-1037.
22. Hall PA, Coates PJ. Assessment of cell proliferation in pathology - what next? Histopathology 1995; 26: 105-112.
23. Fåhraeus R, Fischer P, Krausz E, Lane DP. New approaches to cancer therapies. J Pathol 1999; 187: 138-146.